On 14 July 2026, Formycon and OneSource Speciality Pharma announced that they have entered into a strategic manufacturing partnership for biosimilars. OneSource is an Indian-based specialty pharma Contract Development & Manufacturing Organisation (CDMO) that provides end-to-end services for complex pharmaceutical products.
Under the partnership, OneSource will provide integrated drug substance and drug product manufacturing capabilities from its biologics facility in Bangalore, to support the development of Formycon’s biosimilar programs for global markets.
Formycon’s CEO, Dr Stefan Glombitza, stated that “by adding OneSource to our network of strategic manufacturing partners, we are further strengthening our supply capabilities”. Neeraj Sharma, OneSource’s Managing Director & CEO, added that this partnership “…reinforces our belief that India is uniquely positioned to serve as a global hub for the development and manufacturing of world-class biologics”.
In June 2025, Sweden-based Xbrane Biopharma and OneSource entered into a partnership for the commercial manufacture of Xbrane’s biosimilar portfolio.